The following is a summary of the DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript:

Financial Performance:

• DiaMedica reported a combined cash, cash equivalents, and investments balance of $50.2 million as of September 30, 2024.

• Net cash used in operating activities for the 9-month period ending September 30, 2024, increased to $15.6 million.

• Research and development expenses for the 9 months ended September 30, 2024, were $12.6 million, showing a significant investment in ongoing clinical trials.

Business Progress:

• DiaMedica expressed progress in both stroke and preeclampsia programs, anticipating a transformative year in 2025.

• Advances included activating major U.S. sites for the AIS study, with contracts signed for top sites.

• They secured regulatory approval for their preeclampsia program in South Africa, with their first patient enrolled recently.

Opportunities:

• Expansion of clinical trial sites in the U.S. and Canada, alongside adjustments to the ReMEDy2 trial to include more responsive subgroups, is expected to enhance patient enrollment and trial effectiveness.

• Anticipated improvements in the commercial and clinical potential of DM199 through greater inclusivity in trial participant criteria.

Risks:

• Complex protocol adjustments and enlargement of the sample size for interim analysis which introduces potential delays and necessitates meticulous execution to avoid pitfalls associated with rapid scaling.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.